The Design and Synthesis of Selective Prostaglandin Analogs as Bone Anabolic Agents for the Potential Treatment of Osteoporosis

Advances in Experimental Medicine and Biology

Volumn 507, Issue , 2002, Pages 303-307

  Soper, David Lindsey ^a   Wang, Yili ^a   De, Biswanath ^a   DeLong, Mitchell Anthony ^a   Dirr, Michelle Jeanine ^a   Soehner, Michele Elaine ^a   Lundy, Mark Walden ^a   Mieling, Glen Edward ^a   Wos, John August ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F RECEPTOR; PROSTAGLANDIN RECEPTOR; UNCLASSIFIED DRUG; FLUPROSTENOL; PROSTAGLANDIN F;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BONE DEVELOPMENT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; ARTICLE; BONE; CHEMICAL STRUCTURE; DRUG DESIGN; DRUG EFFECT; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNTHESIS;

ANIMALIA;

BONE AND BONES; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OSTEOPOROSIS; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038784221     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0193-0_46     Document Type: Conference Paper

References (11)

1. a) Ueda, K.; Saito, S.; Najano, H.; Aoshima, M.; Yokata, M.; Muraoka, R. ; Iwaya, T. Cortical hyperostosis following long-term administration of prostaglandin E-1 in infants with cyanotic congential heart disease. J. Pediatr. 1980, 97, 834-836.
2. (b) Ueno, K.; Haba, T.; Woodbury, D.; Price, P.; Anderson, R.; Jee, W.S.S. The effects of prostaglandin E2 in rapidly growing rats: Depressed longitudinal and radial growth and increased metaphyseal hard tissue mass. Bone 1985, 6, 79-86.
3. α on the skeleton of osteopenic ovariectomized rats. Bone 1995, 17, 549-554.
4. (d) Jee, W.S.S.; Ma, Y.F. The in vivo anabolic actions of prostaglandins in bone. Bone 1997, 21, 297-304.
5. 2 increases bone strength in intact rats and ovariectomized rats with established osteoporosis. Bone 1998, 23, 249-255.
6. (a) Negishi, M.; Sugimoto, Y.; Ichikawa, A. Molecular mechanism of diverse actions of prostanoid receptors. Biochim. Biophy. Acta 1995, 1259, 109-120.
7. (b) Abramovitz, M.; Metters, K.M. Prostanoid Receptors. Ann. Rep. Med Chem. 1998, 33, 223-232.
8. 1 prostanoid receptor. Bioorganic Med. Chem. Lett. 1999, 9, 2699-2705.
9. 1α analogs as potent and selective ligands for the human FP receptor. J. Med. Chem. 2000, in press.
10. (d) Hartke, J. R.; Jankowsky, M. L.; deLong, M. A.; Soehner, M. E.; Jee, W. S. S.; Lundy, M. W. Prostanoid FP agonists build bone in the ovariectomized rat. Journal Of Bone And Mineral Research 1999 Vol. 14, Suppl. 1, S207.
11. (e) deLong, M. A.; Hartke, J. R.; Jankowsky, M. L.; Soehner, M. E.; Wos, J. A.; Soper, D. L. Lundy, M. W. Tetrahydro-fluprostenol, a 17-phenyl saturated prostanoid FP receptor agonist, is a bone anabolic agent in the aged, ovx rat. Journal Of Bone And Mineral Research 1999 Vol.14, Suppl. 1, S275